Crossmark

The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials

Crossref DOI link: https://doi.org/10.1038/s41467-025-62260-5

Published Online: 2025-07-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qian, Xiao

Ning, Weihai

Yang, Jingjing

Dunmall, Louisa Chard https://orcid.org/0000-0003-2380-0900
Pandha, Hardev S.

Shang, Guanjie

Guo, Yuduo

Zhang, Dongxu

Qu, Yanming

Wang, Haoran

Gu, Chunyu

Zhang, Mingshan

Wang, Yaohe https://orcid.org/0000-0003-2367-6313
Wang, Shengdian https://orcid.org/0000-0002-9626-7900
Zhang, Hongwei https://orcid.org/0000-0002-4508-7678
License Information

Text and Data Mining valid from 2025-07-28

Version of Record valid from 2025-07-28
More Information

Article History

Received: 4 June 2025

Accepted: 10 July 2025

First Online: 28 July 2025

Competing interests

: Yaohe Wang is an inventor of the patent of Ad-TD-nsIL12 (Modified interleukin 12 and its use in manufacture of a medicament for treatment of tumors, PCT/CN2016/098527). All other authors declare no conflict of interest.

Document is current

Any future updates will be listed below